Stocks · News reference
Aligos Therapeutics released its Q3 2026 financial results, noting a narrowed operating loss and cash runway projections.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Aligos Therapeutics reported positive data from five presentations at the AASLD's The Liver Meeting 2026, highlighting advancements in its pipeline for liver and viral diseases.
Filed: 2026-11-06 AccNo: 0001171843-26-007214 Size: 263 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026SOUTH